Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392060 | 0.90 | MTNR1A (0.60) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL3390898 | 0.90 | MTNR1A (0.60) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL5522805 | 0.90 | MTNR1A (0.60) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL3796486 | 0.87 | NPC1 (0.62) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL5439855 | 0.86 | NPC1 (0.56) | NPC1RAB9AGRM7KMT2AMEN1 | |
| SCHEMBL2077838 | 0.85 | GRM7 (0.51) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL27531958 | 0.85 | NPC1 (0.49) | NPC1RAB9AGRM7MCHR1SLC6A12 | |
| SCHEMBL2079473 | 0.84 | APOB (0.57) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8161785 | 0.83 | NPC1 (0.73) | NPC1RAB9AGRM7KMT2AMEN1 | |
| SCHEMBL2078815 | 0.83 | NPC1 (0.54) | NPC1RAB9AGRM7MCHR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2198861-B1 | eNOS transcription enhancers for use in the cell therapy of limb ischemia | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-06-25 | — | — | EP | claimed |
| US-20130123354-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | claimed |
| US-8309608-B2 | Endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells; for treating cardiomyopathy, congestive heart failure | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-11-13 | — | — | US | claimed |
| JP-4705581-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| EP-2198861-A2 | eNOS transcription enhancers for use in the cell therapy of ischemic heart diseases | Sanofi-Aventis Deutschland GmbH (DE) | 2010-06-23 | — | — | EP | claimed |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-1682111-B1 | ENOS TRANSCRIPTION ENHANCERS FOR USE IN THE CELL THERAPY OF ISCHEMIC HEART DISEASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-06 | — | — | EP | claimed |
| CN-100563643-C | Endothelial nitric oxide synthase transcription enhancer for cell therapy of ischemic heart disease | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-02 | — | — | CN | claimed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | claimed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20050054729-A1 | 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1159258-B1 | AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-10 | — | — | EP | claimed |
| US-6812253-B2 | STIMULATING THE EXPRESSION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE FOR TREATING CARDIOVASCULAR DISORDERS, STROKE, THROMBOSIS, ATHEROSCLEROSIS, SEXUAL DISORDERS, DIABETES, ANGIOGENESIS, ASTHMA BRONCHIALE, RENAL FAILURE, CIRRHOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-02 | — | — | US | claimed |
| CN-1170814-C | Amide compounds for potentiation of cholinergic activity | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | claimed |
| US-20040019114-A1 | 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-29 | — | — | US | claimed |
| US-6664293-B2 | For treatment and/or prevention of disorders in the central nervous system, particularly amnesia, dementia, Alzheimer's dementia | FUJIWAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | claimed |
| EP-1361882-A1 | 4-FLUORO-N-INDAN-2-YL BENZAMIDE AND ITS USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-11-19 | — | — | EP | claimed |
| US-6617359-B2 | Stimulating the expression of endothelial NO(nitric oxide)-synthase in a mammal by administering 4-fluoro-N-indan-2-yl benzamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | claimed |
| US-20030022939-A1 | 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | claimed |
| WO-2002064146-A1 | 4-FLUORO-N-INDAN-2-YL BENZAMIDE AND ITS USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | NPC1 178/4885RAB9A 1417/4885GRM7 1240/4885 |
| US-20040019114-A1 | 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical | PTGIS, PTGIR, PGF | NPC1 1382/4885RAB9A 2205/4885GRM7 3190/4885 |
| US-20050054729-A1 | 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical | PTGIS, PTGIR, PGF | NPC1 1681/4885RAB9A 2020/4885GRM7 3304/4885 |
| US-20130123354-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | NPC1 178/4885RAB9A 1417/4885GRM7 1240/4885 |
| US-20030022939-A1 | 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical | PTGIS, PTGIR, PGF | NPC1 1382/4885RAB9A 2205/4885GRM7 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.